| Literature DB >> 23418854 |
Svend Kjær1, Mark Linch, Andrew Purkiss, Brenda Kostelecky, Phillip P Knowles, Carine Rosse, Philippe Riou, Christelle Soudy, Sarah Kaye, Bhavisha Patel, Erika Soriano, Judith Murray-Rust, Caroline Barton, Christian Dillon, Jon Roffey, Peter J Parker, Neil Q McDonald.
Abstract
The aPKC [atypical PKC (protein kinase C)] isoforms ι and ζ play crucial roles in the formation and maintenance of cell polarity and represent attractive anti-oncogenic drug targets in Ras-dependent tumours. To date, few isoform-specific chemical biology tools are available to inhibit aPKC catalytic activity. In the present paper, we describe the identification and functional characterization of potent and selective thieno[2,3-d]pyrimidine-based chemical inhibitors of aPKCs. A crystal structure of human PKCι kinase domain bound to a representative compound, CRT0066854, reveals the basis for potent and selective chemical inhibition. Furthermore, CRT0066854 displaces a crucial Asn-Phe-Asp motif that is part of the adenosine-binding pocket and engages an acidic patch used by arginine-rich PKC substrates. We show that CRT0066854 inhibits the LLGL2 (lethal giant larvae 2) phosphorylation in cell lines and exhibits phenotypic effects in a range of cell-based assays. We conclude that this compound can be used as a chemical tool to modulate aPKC activity in vitro and in vivo and may guide the search for further aPKC-selective inhibitors.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23418854 DOI: 10.1042/BJ20121871
Source DB: PubMed Journal: Biochem J ISSN: 0264-6021 Impact factor: 3.857